港股异动 | 康方生物(09926)涨超8% 依沃西HARMONi-6研究结果将于《柳叶刀》和ESMO LBA同步发表

智通财经
Oct 16

智通财经APP获悉,康方生物(09926)涨超8%,截至发稿,涨6.97%,报130.5港元,成交额7.49亿港元。

消息面上,据康方生物官微消息,10月16日,康方生物自主研发的全球首创双特异性抗体新药依沃西(PD-1/VEGF双抗)联合化疗对比替雷利珠单抗联合化疗,用于一线治疗晚期鳞状非小细胞肺癌(sq-NSCLC)的注册性III期临床研究(AK112-306/HARMONi-6)研究成果,已被国际顶级医学期刊《柳叶刀》(THE LANCET)主刊接收,将在2025年欧洲肿瘤内科学会(ESMO 2025)大会期间同期发表,重磅结果即将闪耀全球科研舞台。

据介绍,目前该研究成果已成功入选2025年ESMO Late-Breaking Abstract(LBA),并将在ESMO年会最受瞩目的主席论坛(Presidential Symposium)上,将由主要研究者、上海市胸科医院肿瘤科主任陆舜教授作口头报告,向全球肿瘤学界展示依沃西联合化疗与当前肿瘤免疫治疗应用最广泛的PD-1联合化疗组合“头对头”III期临床研究的卓越成果。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10